Leif E. Pedersen Sells 51,224 Shares of Certara, Inc. (NASDAQ:CERT) Stock

Certara, Inc. (NASDAQ:CERT) insider Leif E. Pedersen sold 51,224 shares of Certara stock in a transaction dated Monday, September 9th. The shares were sold at an average price of $11.29, for a total transaction of $578,318.96. Following the completion of the sale, the insider now owns 99,704 shares in the company, valued at $1,125,658.16. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink.

Certara Price Performance

NASDAQ:CERT opened at $10.98 on Thursday. The company has a quick ratio of 2.61, a current ratio of 2.61 and a debt-to-equity ratio of 0.28. The business’s 50-day moving average price is $13.74 and its 200 day moving average price is $15.70. Certara, Inc. has a 52-week low of $10.72 and a 52-week high of $19.87. The firm has a market cap of $1.77 billion, a P/E ratio of -28.15, a PEG ratio of 5.31 and a beta of 1.50.

Certara (NASDAQ:CERT) last released its earnings results on Tuesday, August 6th. The company reported $0.07 EPS for the quarter, missing analysts’ consensus estimates of $0.10 by ($0.03). The business had revenue of $93.31 million during the quarter, compared to the consensus estimate of $96.01 million. Certara had a positive return on equity of 3.03% and a negative net margin of 21.64%. The firm’s revenue for the quarter was up 3.2% compared to the same quarter last year. During the same quarter in the previous year, the firm earned $0.10 earnings per share. As a group, sell-side analysts predict that Certara, Inc. will post 0.28 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Certara

Several large investors have recently modified their holdings of CERT. Algert Global LLC acquired a new stake in shares of Certara during the second quarter worth $156,000. Select Equity Group L.P. increased its stake in Certara by 19.6% in the 2nd quarter. Select Equity Group L.P. now owns 159,008 shares of the company’s stock worth $2,202,000 after purchasing an additional 26,095 shares in the last quarter. The Manufacturers Life Insurance Company raised its holdings in Certara by 4.5% during the 2nd quarter. The Manufacturers Life Insurance Company now owns 22,871 shares of the company’s stock worth $317,000 after buying an additional 975 shares during the period. Daventry Group LP lifted its stake in Certara by 153.0% during the second quarter. Daventry Group LP now owns 1,308,572 shares of the company’s stock valued at $18,124,000 after buying an additional 791,405 shares in the last quarter. Finally, Squarepoint Ops LLC acquired a new position in shares of Certara in the second quarter worth about $311,000. 73.96% of the stock is owned by institutional investors.

Wall Street Analyst Weigh In

Several brokerages have recently issued reports on CERT. KeyCorp reduced their price objective on Certara from $23.00 to $20.00 and set an “overweight” rating for the company in a research report on Thursday, July 11th. JMP Securities reissued a “market perform” rating on shares of Certara in a research note on Wednesday, July 10th. Barclays lowered their price target on Certara from $18.00 to $16.00 and set an “equal weight” rating on the stock in a report on Friday, June 28th. UBS Group reduced their price objective on shares of Certara from $20.00 to $16.00 and set a “neutral” rating for the company in a report on Wednesday, August 7th. Finally, Robert W. Baird lowered their target price on shares of Certara from $19.00 to $18.00 and set a “neutral” rating on the stock in a research note on Wednesday, August 7th. Seven equities research analysts have rated the stock with a hold rating and two have given a buy rating to the stock. Based on data from MarketBeat, the stock has a consensus rating of “Hold” and an average price target of $17.79.

About Certara

Certara, Inc, together with its subsidiaries, provides software products and technology-enabled services to customers for biosimulation in drug discovery, preclinical and clinical research, regulatory submissions, and market access in the United States and internationally. It offers solutions for model-informed drug development, as well as biosimulation solution used to predict both pharmacokinetics and pharmacodynamics.